Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Abeona Therapeutics (ABEO) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Abeona Therapeutics (ABEO) over the last 13 years, with Q2 2025 value amounting to 27213.75%.

  • Abeona Therapeutics' EBITDA Margin changed N/A to 27213.75% in Q2 2025 from the same period last year, while for Sep 2025 it was 20611.0%, marking a year-over-year change of. This contributed to the annual value of 1546.43% for FY2023, which is 15356100.0% up from last year.
  • Abeona Therapeutics' EBITDA Margin amounted to 27213.75% in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' EBITDA Margin ranged from a high of 97293.75% in Q4 2021 and a low of 10597.06% during Q4 2022
  • Its 4-year average for EBITDA Margin is 12161.86%, with a median of 1014.07% in 2021.
  • In the last 5 years, Abeona Therapeutics' EBITDA Margin soared by 978222500bps in 2021 and then plummeted by -1078908100bps in 2022.
  • Over the past 4 years, Abeona Therapeutics' EBITDA Margin (Quarter) stood at 97293.75% in 2021, then tumbled by -111bps to 10597.06% in 2022, then skyrocketed by 96bps to 476.69% in 2023, then skyrocketed by 5809bps to 27213.75% in 2025.
  • Its EBITDA Margin was 27213.75% in Q2 2025, compared to 476.69% in Q2 2023 and 10597.06% in Q4 2022.